Validity and representativeness of the "Disease Analyzer" patient database for use in pharmaco-epidemiological and pharmacoeconomic studies

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 10, 2009, Pages 617-626

  Becher, H ^a   Kostev, K ^b   Schroder Bernhardi D ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b IQVIA   (United States)

Author keywords

Epidemiological studies; Patient database; Validation criteria

Indexed keywords

GENERIC DRUG; PRESCRIPTION DRUG;

ARTICLE; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MEDICAL PRACTICE; MEDICAL RECORD; MEDICAL SOCIETY; MEDICAL SPECIALIST; OBESITY; PATIENT DATABASE; PHARMACOECONOMICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; RISK FACTOR; SMOKING; ADULT; AGED; CLINICAL PRACTICE; ECONOMICS; EPIDEMIOLOGY; FACTUAL DATABASE; FEMALE; GERMANY; MALE; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHYSICIAN; STANDARD; STATISTICS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; ECONOMICS, PHARMACEUTICAL; EPIDEMIOLOGIC METHODS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTION DRUGS;

EID: 70350741664     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47617     Document Type: Article

References (45)

1. Ahrens W, Hagemeier C, Mühlbauer B, Pigeot I, Püntmann I, Reineke A, Steinbach M, Timm J. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf. 2007; 16: 1298-1307.
2. Altenhofen L, Hagen B, Haß W. DMP Diabetes mellitus Typ 2: Was zeigen die bisherigen Daten aus Nordrhein. Kirchheimforum Diabetes 2006 in Münster, 2006.
3. Andersohn F, Garbe E. Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008; 51: 1135-1144 (in German).
4. Ärztestatistik der Bundesärztekammer. (Physicians' statistics of the German Medical Association) 2007, http://www.baek.de.
5. Benson K, Hartz AJ. A comparison of observation studies and randomised, controlled trials. N Engl J Med. 2000; 342: 1878-1886.
6. BKK. BKK Gesundheitsreport 2005, (accessed August 16, 2007). www.bkk.de/htdocs/bkk/psfile/downloaddatei/64/ Gesundheit438ae1c8de09a.pdf.
7. Burkowitz J, Brüggenjürgen B. Resource utilisation of patients with chronic pain conditions before and during treatment with long-acting opioids in Germany. Value in Health. 2004; 7: 725.
8. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observation studies, and the hierarchy of research design. N Engl J Med. 2000; 342: 1887-1892.
9. Dietlein G, Schröder-Bernhardi D. Use of the mediplus patient database in healthcare research. Int J Clin Pharmacol Therap. 2002; 40: 130-133.
10. Dietlein G, Schröder-Bernhardi D. Doctor's prescription behavior regarding dosage recommendations for preparations of kava extracts. Pharmacoepidemiol Drug Saf. 2003; 12: 417-421.
11. Farmer RDT, Todd J-C, MacRae KD, Williams TJ, Lewis MA. Oral contraception was not associated with venous thromboembolic disease in recent study. BMJ. 1998a; 316: 1090-1091.
12. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception. 1998b; 57: 67-70.
13. Feige A, Rempen A, Würfel W, Jawny J, Caffier H. Frauenheilkunde, 2nd edition, München-Jena: Urban & Fischer Verlag; 2001.
14. Gaus W, Westendorf J, Diebow R, Kieser M. Identification of adverse drug reactions by evaluation of a prescription database. Methods Inf Med. 2005; 44: 697-703.
15. Glaeske G, Janhsen K. GEK Arzneimittelreport 2005, Schriftenreihe zur Gesundheitsanalyse, Band 36. Sankt Augustin: Asgard; 2005.
16. Glaeske G, Janhsen K. GEK Arzneimittelreport 2007, Schriftenreihe zur Gesundheitsanalyse, Band 55, Bremen-Schwäbisch Gmünd; June 2007.
17. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care-a large-scale follow-up study. Eur J Clin Pharmacol. 2007; 63: 783-790.
18. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol. 2003; 18: 237-242.
19. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. Journal of Human Hypertension. 2002; 16: 569-575.
20. Hasford J, Schubert I, Garbe E, Dietlein G, Glaeske G. Memorandum zu Nutzen und Notwendigkeit Pharmakoepidemiologischer Datenbanken in Deutschland (GEK-Edition; Band 33). Hippe: Asgard-Verlag; 2004.
21. Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence in Hypertension. Eur J Clin Pharmacol. 2007; 63: 1055-1061.
22. Hauner H, Köster I, von Ferber L. Ambulante Versorgung von Patienten mit Diabetes mellitus, Deutsche Medizinische Wochenschrift. 2003; 128: 2638-2643.
23. Icks A, Haastert B, Giani G, Rathmann W. Incremental prescription and drug costs during the years preceding diabetes diagnosis in primary care practices in Germany. Exp Clin Endocrinol Diabetes. 2006; 114: 348-355.
24. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy. 2003; 23: 686-689.
25. Krobot KJ, Schröder-Bernhardi D, Pfaffenrath V. Migraine consultation patterns in primary care. Cephalalgia. 1999a; 19: 831-840.
26. Krobot KJ, Steinberg HW, Pfaffenrath V. Migraine prescription density and recommendations. Results of the PCAOM study. Cephalalgia. 1999b; 19: 511-519.
27. Krobot KJ et al. Quantifying delay in access to new medical treatment: an application of risk advancement period methodology. Epidemiology. 2004; 15: 202-207.
28. Linsell L, Dawson J, Zondervan K, Randall T. Prospective study of elderly people comparing trearments following first primary care consultation for a symptomatic hip or knee. Fam Pract. 2005; 22: 118-125.
29. Mockenhaupt M, Schlingmann J, Schröder W, Rathmann W, Schöpf E, Martinez C. Severe Cutaneous Adverse Reactions (SCAR): The Risk for Diabetes Mellitus and Anti-infective Sulphonamides. B J Dermatol. 1998; 138: 374-377.
30. Mockenhaupt M, Messenheimer J, Tennis P. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005; 64: 1134-1138.
31. Perez E, Schröder-Bernhardi D, Dietlein G. Treatment behavior of doctors regarding Helicobacter pylori infections. Int J Clin Pharmacol Ther. 2002; 40: 126-129.
32. Rathmann W, Haastert B, Delling B, Gries FA, Giani G. Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources. Pharmacoepidemiol Drug Safety. 1998a; 7: 51-57.
33. Rathmann W, Haastert B, Roseman J, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care. 1998b; 21: 389-397.
34. Rathmann W, Haastert B, Roseman J, Gries FA, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999; 52: 1103-1109.
35. Robert Koch Institut. Krebs in Deutschland, Schätzung des Robert Koch-Instituts. (accessed August 16, 2008.) http://www.rki.de/ cln_091/nn_204078/DE/Content/GBE/DachdokKrebs/Datenbankabfragen/ Neuerkrankungen/neuerkrankungen__node.html?__nnn=true.
36. Rodriguez LA, Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmocol. 1998; 45: 419-426.
37. Sauer H, Artmann A, de Waal JC, Eiermann W, Gutschow K, Harbeck N, Heinemann V, Kessler M, Lutz L, Mahl G, Prechtl A, Rauthe G, Schmid L, Sittek H, Sommer H, Stieber P, Untch M, Wuttge-Hannig A. Nachsorge, Manual Mammakarzinome, Tumorzentrum München (ed.). München: W. Zuckschwerdt Verlag; 2003.
38. Schröder-Bernhardi D, Dietlein G. Compliance with prescription recommendations by physicians in practices. Int J Clin Pharmacol Ther. 2001; 39: 477-479.
39. Schröder-Bernhardi D, Dietlein G. Lipid lowering therapy: do hospitals influence the prescription behavior of general practitioners? Int J Clin Pharmacol Ther. 2002; 40: 317-321.
40. Schröder-Bernhardi D, Roth K, Dietlein G. Off-label-use of PPI andβ-blockers in general practices. Int J Clin Pharmacol Ther. 2004; 42: 581-588.
41. Schwabe U, Pfaffrath D. Arzneiverordnungsreport 2005, Heidelberg: Springer Verlag; 2005.
42. Schwabe U, Pfaffrath D. Arzneiverordnungsreport 2006. Heidelberg: Springer Verlag; 2006.
43. Sittl R, Nuitjen M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany. Clin Ther. 2005; 27: 1022-1031.
44. Statistisches Bundesamt. www.eds-destatis.de
45. von Zepelin H-H, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer, Int J Clin Pharmacol Ther. 2007, 45: 143-154.